Laboratorios Farmaceuticos RoviLABFF 93 Return-on-Tangible-Asset is 4.16% as of Mar. 2026, which is 71% below its 10-year median of 14.29. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 89.15% on this metric.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Asset or its related term are showing as below:
LABFF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.6 Med: 14.29 Max: 25.98
Current: 15.29
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest Return-on-Tangible-Asset was 25.98%. The lowest was 5.60%. And the median was 14.29%.
LABFF's Return-on-Tangible-Asset is ranked better than 89.15% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.17
vs LABFF: 15.29
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Laboratorios Farmaceuticos Rovi Return-on-Tangible-Asset Related Terms
Laboratorios Farmaceuticos Rovi Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LABFF vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 4.16% mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Return-on-Tangible-Asset of 4.16% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 71% below median its historical median of 14.29. Over the past decade, Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Asset has ranged from 5.60 to 25.98. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #109 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 10.8%.
Is Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Asset too high?
Laboratorios Farmaceuticos Rovi's current Return-on-Tangible-Asset of 4.16% is 71% below median its 10-year median of 14.29. Over the past 10 years, this metric has ranged from a low of 5.60 to a high of 25.98. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.17. Laboratorios Farmaceuticos Rovi's value of 4.16% is 31.2% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #109 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #109 out of 1005 companies for Return-on-Tangible-Asset. This places Laboratorios Farmaceuticos Rovi in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.17. Laboratorios Farmaceuticos Rovi's value of 4.16% is 31.2% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Return-on-Tangible-Asset has ranged from 5.60 to 25.98 over the past decade. While the company's 10-year median is 14.29 vs. the industry median of 3.17, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.17, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Return-on-Tangible-Asset of 4.16% is 31.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Return-on-Tangible-Asset is 4.16%, which is 71% below median its own 10-year median of 14.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Return-on-Tangible-Asset of 4.16%. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current Return-on-Tangible-Asset is 4.16%, which is 71% below median its 10-year median of 14.29 and 31.2% above the Drug Manufacturers industry median of 3.17. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Return-on-Tangible-Asset is 4.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
Return-on-Tangible-Asset: 4.16% (71% below median its 10-year median of 14.29)
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
Industry Position: 31.2% above the Drug Manufacturers median (#109 of 1005)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
